TrialSignal transduction and targeted therapy2026

Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer.

Anmbreen Jamroze et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.